The FDA has granted Merck’s insulin glargine (Lusduna Nexvue) tentative approval. Merck says that its follow-on basal insulin has met all required regulatory standards of clinical and nonclinical safety, efficacy, and quality for follow-on biologics.
The FDA has granted Merck’s insulin glargine (Lusduna Nexvue) tentative approval. Merck says that its follow-on basal insulin has met all required regulatory standards of clinical and nonclinical safety, efficacy, and quality for follow-on biologics. “The tentative approval of Lusduna Nexvue is an important milestone, bringing us closer to offering this medicine to patients,” said Sam Engel, MD, associate vice president of Merck clinical research, diabetes, endocrinology and women’s health.
The FDA will not issue its final approval, however, until patent infringement litigation, brought by Sanofi, has concluded. Sanofi, maker of Lantus, contends that Merck has infringed upon its patents for insulin glargine, and its suit triggered an automatic stay on the FDA’s final approval of up to 30 months (unless the US District Court hearing the case rules in favor of Merck, in which case final approval may proceed immediately).
After litigation has concluded, Lusduna will not only compete with Lantus in the US market, but also with Boehringer Ingelheim (BI)'s Basaglar, the first follow-on insulin glargine product approved by the FDA. In its first quarter on the market, Basaglar earned $22 million in US sales, and $46 million worldwide. BI received approval for the follow-on insulin glargine in late 2015, but Basaglar did not become available in the US marketplace until the following year, when BI reached a settlement with Sanofi in its own litigation.
Merck, like BI, will have to address patent infringement claims under the Hatch-Waxman Act, which governs the generic drug approval process, rather than under the Biologics Price Competition and Innovation Act and the so-called “patent dance.” In the United States, innovator insulins are regulated as drugs, rather than as biologic products that fall under the Public Health Service (PHS) Act. Products that are approved and regulated under the PHS Act must, according to the act’s Section 351, be categorized as blood-derived products, vaccines, in vivo diagnostic allergenic products, immunoglobulin products, products containing cells or microorganisms, and most protein products. That leaves hormone products like insulin (as well as glucagon and human growth hormone), to be regulated under the Food, Drug, and Cosmetic Act.
The FDA’s approach to the approval and regulation of insulins stands in contrast to the European Medicines Agency’s approach, which treats such products—and low-molecular-weight heparin products like enoxaparin—as biosimilars. Lusduna was issued a marketing authorization as a biosimilar in the European Union in April of this year, where it is undergoing additional monitoring.
Follow-on versions of insulin glargine are widely expected to generate cost savings in the treatment of diabetes, but experts point out that the regulatory pathway for such drugs requires a wealth of clinical trial data, and that the design and development costs for delivery devices also pose a substantial cost challenge. According to some estimates, it could be 2018 before enough follow-on insulin glargine products are competing with Lantus in order to drive significant cost-savings for both payers and patients.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.